The Role of Atomoxetine for Parkinson Disease-Related Executive Dysfunction: A Systematic Review
- PMID: 30346335
- DOI: 10.1097/JCP.0000000000000963
The Role of Atomoxetine for Parkinson Disease-Related Executive Dysfunction: A Systematic Review
Abstract
Background: Atomoxetine selectively inhibits the reuptake of norepinephrine. Given the noradrenergic system's role in executive function, pharmacotherapy options that affect norepinephrine are of particular clinical interest in Parkinson disease-related executive dysfunction.
Objective: The aim of this study was to assess the efficacy and safety of atomoxetine for Parkinson disease-related executive dysfunction.
Methods: MEDLINE (1946 to May 2018) and EMBASE (1947 to May 2018) were queried using the search term combination: Parkinson's disease, Parkinson disease, inhibition, impulse behavior, impulse control disorder, executive function, executive dysfunction, cognition, cognitive dysfunction, cognitive defect, response inhibition, strategic planning, strategy, or verbal fluency and atomoxetine hydrochloride or atomoxetine. Studies analyzed for relevance evaluated clinical outcomes of patients treated with atomoxetine for Parkinson disease-related executive dysfunction. Studies appropriate to the objective were evaluated, including 1 open-label flexible dose trial, 2 placebo-controlled longitudinal trials, and 4 placebo-controlled crossover single-dose trials.
Results: In patients with Parkinson disease, treatment with atomoxetine resulted in improvements in several markers of executive dysfunction including impulsivity, risk taking, and global cognition. Study durations ranged from single-dose trials to 10 weeks and used varying doses of atomoxetine. Atomoxetine was well tolerated in most studies with some reports of gastrointestinal adverse effects and insomnia.
Conclusions: Based on the reviewed literature, atomoxetine continues to be a therapy of interest for the treatment of executive dysfunction in patients with Parkinson disease. Larger long-term trials are necessary to further define the role of atomoxetine for patients with Parkinson disease-related executive dysfunction.
Similar articles
-
Atomoxetine restores the response inhibition network in Parkinson's disease.Brain. 2016 Aug;139(Pt 8):2235-48. doi: 10.1093/brain/aww138. Epub 2016 Jun 24. Brain. 2016. PMID: 27343257 Free PMC article. Clinical Trial.
-
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.Mov Disord. 2009 Jan 30;24(2):277-82. doi: 10.1002/mds.22307. Mov Disord. 2009. PMID: 19025777 Free PMC article. Clinical Trial.
-
Atomoxetine improves memory and other components of executive function in young-adult rats and aged rhesus monkeys.Neuropharmacology. 2019 Sep 1;155:65-75. doi: 10.1016/j.neuropharm.2019.05.016. Epub 2019 May 18. Neuropharmacology. 2019. PMID: 31108108 Free PMC article.
-
Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.Postgrad Med. 2015;127(7):686-701. doi: 10.1080/00325481.2015.1081046. Postgrad Med. 2015. PMID: 26343377 Review.
-
Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Paediatr Drugs. 2009. PMID: 19445548 Review.
Cited by 7 articles
-
Unraveling Targetable Systemic and Cell-Type-Specific Molecular Phenotypes of Alzheimer's and Parkinson's Brains With Digital Cytometry.Front Neurosci. 2020 Dec 9;14:607215. doi: 10.3389/fnins.2020.607215. eCollection 2020. Front Neurosci. 2020. PMID: 33362460 Free PMC article.
-
Neurobiology and clinical features of impulse control failure in Parkinson's disease.Neurol Res Pract. 2019 Mar 20;1:9. doi: 10.1186/s42466-019-0013-5. eCollection 2019. Neurol Res Pract. 2019. PMID: 33324875 Free PMC article. Review.
-
Pharmacological evidence for the implication of noradrenaline in effort.PLoS Biol. 2020 Oct 12;18(10):e3000793. doi: 10.1371/journal.pbio.3000793. eCollection 2020 Oct. PLoS Biol. 2020. PMID: 33044952 Free PMC article.
-
Toward heterogeneous information fusion: bipartite graph convolutional networks for in silico drug repurposing.Bioinformatics. 2020 Jul 1;36(Suppl_1):i525-i533. doi: 10.1093/bioinformatics/btaa437. Bioinformatics. 2020. PMID: 32657387 Free PMC article.
-
Cognition Deficits in Parkinson's Disease: Mechanisms and Treatment.Parkinsons Dis. 2020 Mar 24;2020:2076942. doi: 10.1155/2020/2076942. eCollection 2020. Parkinsons Dis. 2020. PMID: 32269747 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical